Status:
COMPLETED
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Lead Sponsor:
University of California, San Diego
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Treatment of schizophrenia currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psychosocia...
Detailed Description
Treatment of schizophrenia (SZ) currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psycho...
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of schizophrenia or schizoaffective disorder
- Written informed consent to participate in the study
- Age 18-65
- Absence of dementia or mental retardation
- Urine toxicology negative for recreational drugs
- Fluent and literate in English
Exclusion
- Meets DSM-IV criteria for current substance abuse or dependence and has been substance abstinent for less than 30 days
- A history of traumatic brain injury
- Auditory or visual impairments severe enough to prevent study participation
- Under conservatorship (determined by Anasazi)
- Pregnancy
Key Trial Info
Start Date :
July 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2025
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT04857983
Start Date
July 6 2021
End Date
March 30 2025
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Teaching Facility (CTF B-403 at UCSD Medical Center)
San Diego, California, United States, 92103